Press Releases

Keyword Search
 
PDS Biotechnology | Former Edge Therapeutics
July 3, 2019 - PDS Biotechnology Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Read More
June 19, 2019 - PDS Biotechnology Corporation Granted U.S. and European Patents for Versamune® - GM-CSF Combination to Overcome Tumor Immune Suppression
Read More
May 29, 2019 - PDS Biotechnology Signs Cooperative Research and Development Agreement with National Cancer Institute to Perform a Phase 2 Clinical Study of PDS0101 in Combination with Other Immune-modulating Agents in Advanced HPV-related Cancers
Read More
May 28, 2019 - PDS Biotechnology to Present at the 9th Annual LD Micro Invitational
Read More
May 15, 2019 - PDS Biotechnology Announces Publication Supporting Novel Mechanisms of Action of its Proprietary Versamune® Platform in Cancer Immunotherapy
Read More
May 14, 2019 - PDS Biotechnology Reports First Quarter 2019 Financial Results and Provides Business Update
Read More
April 8, 2019 - PDS Biotechnology Appoints Stephen Glover to its Board of Directors
Read More
March 18, 2019 - PDS Biotechnology Completes Merger with Edge Therapeutics
Read More
July 10, 2017 - PDS Biotechnology Corp. Announces Clinical Collaboration with Merck to Evaluate Combination of Versamune® PDS0101 and KEYTRUDA® (pembrolizumab) for Metastatic Head and Neck Cancer
Read More
June 7, 2016 - PDS Biotechnology: CEO Frank Bedu-Addo Presenting at BIO 2016
Read More
April 13, 2016 - PDS Biotechnology Reports Positive Phase 1 Study Results for PDS0101 Immunotherapy for HPV-Related Cancers
Read More
February 9, 2016 - PDS Biotechnology Signs Agreement with National Cancer Institute to form Phase II clinical collaboration for novel cancer immunotherapies based on PDS' Versamune® platform technology
Read More
May 28, 2015 - PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy
Read More
December 18, 2014 - PDS Biotechnology, Inc. Announces Appointment of Biotech Industry Leader Sir Richard Sykes to its Board of Directors as Executive Chairman
Read More
April 16, 2013 - Novel Cancer Immunotherapy set to enter Clinical Trials
Read More
July 9, 2012 - PDS Biotechnology Corporation Signs Worldwide Licensing Agreement with Merck KGaA for Versamune™
Read More
March 2, 2010 - PDS Biotechnology Corporation Awarded $1.28M National Cancer Institute Contract
Read More

Printer Friendly Version Print PageE-mail this page Email PageRSS RSS FeedsE-mail Alerts Email AlertsView contacts IR Contacts